In this issue:
Comparison of first-line treatments for extensive-stage SCLC
Osimertinib in resected EGFR-mutated NSCLC
Pembrolizumab ±RT for metastatic NSCLC
Adding pembrolizumab to chemotherapy in advanced NSCLC without PD-L1 expression
Outcomes associated with definitive RT in metastatic lung cancer
CRT, and subsequent anti-PD-(L)1 therapy, in unresectable, locally advanced NSCLC
NSCLC recurrence following postresection allogenic blood transfusion
Targeted NK-cell-based adoptive immunotherapy for NSCLC after CRT
Osimertinib improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Pembrolizumab + chemotherapy in metastatic squamous NSCLC
Please login below to download this issue (PDF)